The gigantic offer for AstraZeneca by Pfizer is, or should be, a bellwether event. It has nothing obvious to recommend it, except that the US pharmaceuticals group should save on its tax liabilities. That the UK government – allegedly opposed to unfair tax competition – should have made this possible is bad enough. That it should have done so at the expense of one of the UK’s most important companies is worse.
辉瑞(Pfizer)拟斥巨资收购阿斯利康(AstraZeneca)是（或者应该是）一个风向标事件。这没啥好说的，除了这家美国制药集团居然避税以外。据说反对不公平税收竞争的英国政府竟然让辉瑞避税成为可能，这已经够糟糕的了，而更糟糕的是，它这么做竟然是以英国最重要的公司之一为代价的。
您已阅读8%（553字），剩余92%（6086字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。